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T-cells specific for foreign (e.g., viral) antigens can give rise to strong protective immune responses, whereas self/tumor
antigen-specific T-cells are thought to be less powerful. However, synthetic T-cell vaccines composed of Melan-A/MART-1
peptide, CpG and IFA can induce high frequencies of tumor-specific CD8 T-cells in PBMC of melanoma patients. Here we
analyzed the functionality of these T-cells directly ex vivo, by multiparameter flow cytometry. The production of multiple
cytokines (IFNc, TNFa, IL-2) and upregulation of LAMP-1 (CD107a) by tumor (Melan-A/MART-1) specific T-cells was comparable
to virus (EBV-BMLF1) specific CD8 T-cells. Furthermore, phosphorylation of STAT1, STAT5 and ERK1/2, and expression of CD3
zeta chain were similar in tumor- and virus-specific T-cells, demonstrating functional signaling pathways. Interestingly, high
frequencies of functionally competent T-cells were induced irrespective of patient’s age or gender. Finally, CD8 T-cell function
correlated with disease-free survival. However, this result is preliminary since the study was a Phase I clinical trial. We
conclude that human tumor-specific CD8 T-cells can reach functional competence in vivo, encouraging further development
and Phase III trials assessing the clinical efficacy of robust vaccination strategies.
Protection from disease by antigen-speciﬁc CD8 T-cells
depends on their proper activation, with corresponding
increase in T-cell frequency, effector and memory cell differ-
entiation, and development of T-cell functions. Several prop-
erties of T-cells have been established as correlates of protec-
tion from infectious diseases. First, T-cells need to recognize
cognate antigen efﬁciently1–3 (i.e., have good ‘‘functional
avidity’’) which is controlled by T-cell receptors (TCRs) and
coreceptors. Second, the precursor frequency of antigen-spe-
ciﬁc T-cells plays a critical role.4,5 And third, protection
requires functional competence of T-cells, which depends on
intermediate-to-high functional avidity and additional param-
eters. Attempts for a more complete characterization of cor-
relates of protection have focused on direct ex vivo functional
proﬁling of T-cells.6,7 These studies have indicated that
strong cytotoxic activity and production of multiple cytokines
correlates with improved disease outcome.8,9
Mouse models have suggested that tumor immunity may
rely on similar principles as immunity to pathogens. Func-
tional avidity appears to be essential, as well as the capacity
of T-cells to recognize naturally processed and presented tu-
mor antigens.10 Moreover, the precursor frequency of naı¨ve
T-cells plays a key role.11 Finally, it is important that T-cells
are competent for proliferation, cell survival, homing, effector
functions and generation of immunological memory.8,12–14
Activation of protective CD8 T-cells is best achieved by
infection with natural pathogens. Among the commercially
available vaccines, only live vaccines (e.g., smallpox and yel-
low fever vaccines) are capable of inducing large numbers of
pathogen-speciﬁc CD8 T-cells.15 However, live vaccines are
rarely available. As compared to natural infection, most
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synthetic vaccines and cancer vaccines induce much weaker
CD8 T-cell responses which are often unable to contain or
eradicate tumors.16 Among the available low-dose synthetic
vaccines, formulations with antigenic peptides, CpG and IFA
induce the strongest human CD8 T-cell responses.17,18 CpG
and IFA are also excellent adjuvants when using recombinant
proteins instead of peptides, but CD8 T-cell responses are
less potent.19,20 In the present study, we analyzed CD8 T-cell
responses of melanoma patients in unprecedented detail ex
vivo, after vaccination with a low dose vaccine composed of
Melan-A/MART-1 peptide and CpG 7909 (PF-3512676),
emulsiﬁed in IFA. We have previously shown that this
formulation induced high numbers of tumor antigen-speciﬁc
T-cells in 8 of 8 HLA-A2pos patients, and that the majority
of the induced T-cells have high functional avidity and
efﬁciently recognize tumor cells.17 Here we conﬁrm these
ﬁndings in 24 patients and provide the ﬁrst demonstration of
tumor-speciﬁc CD8 T-cells that are multifunctional in vivo.
Methods
Patients, study protocol and eligibility criteria
This prospective Phase I clinical study (ClinicalTrials.gov
Identiﬁer NCT00112229) was performed by the Ludwig Insti-
tute for Cancer Research and the Multidisciplinary Oncology
Center, upon approval by IRBs, Swissmedic and the LICR
Protocol Review Committee. A total of 29 patients were
included, and 24 patients were evaluable for this study, based
on the availability of complete data sets and sufﬁcient lym-
phocytes allowing direct ex vivo analysis of T-cell function.
HLA-A2pos patients with histologically proven metastatic
(stage III/IV) melanoma of the skin expressing Melan-A/
MART-1 (RT PCR or immuno-histochemistry) were included
upon written informed consent. Inclusion criteria were: Kar-
nofsky performance status of 70 %, normal CBC and kid-
ney-liver function, no concomitant antitumor therapy or
immunosuppressive drugs. Exclusion criteria were pregnancy,
seropositivity for HIV-1 Ab or HBs Ag, uncontrolled bleed-
ing, clinically signiﬁcant autoimmune disease and sympto-
matic heart disease (NYHA III-IV). Study end points were
toxicity and CD8 T-cell response.
Study treatment
Patients received monthly low dose vaccinations injected s.c.,
composed of CpG 7909 (PF-3512676) oligonucleotides and
Melan-A/MART-1 peptide, emulsiﬁed in Montanide ISA-51,
as stable emulsion prepared in a syringe. Vaccines for
patients indicated as ‘‘without CpG’’ were prepared similarly
but without CpG. Phosphorothioate backbone CpG 7909
(PF-3512676) oligonucleotides (TCGTCGTTTTGTCGTTTT
GTCGTT) were provided by Pﬁzer and Coley Pharmaceutical
Group, Wellesley MA. Clinically graded peptides were pro-
vided by the LICR, Melbourne (Australia) and NY (USA).
Adjuvant IFA (Incomplete Freund’s Adjuvant; Montanide
ISA-51) consisted of mineral oil (Drakeol) and anhydro
mannitol octadecanoate (Seppic, Paris, France). All compo-
nents were prepared under GMP conditions, and had no
detectable endotoxin by LAL assay.
Blood cells, HLA-A2/peptide tetramers and cytokine
analyses
Ficoll-Paque centrifuged PBMC (1–2  107) were cryopre-
served in RPMI 1640, 40% FCS and 10% DMSO. Phycoery-
thrin-labeled HLA-A*0201/Melan-A/MART-1 A27L pep-
tide26-35 (ELAGIGILTV) and HLA-A*0201/EBV lytic protein
BMLF1280-288 (GLCTLVAML) tetramers were prepared as
descried.17 Anti-CD8, -CD28 and anti-CCR7 mAbs were pur-
chased from BD PharMingen (San Diego, CA), anti-CD45RA
from Beckman Coulter, goat anti-rat IgG Ab (for indirect
staining of CCR7; Caltag Laboratories). All tetramer and anti-
body batches were titrated to determine optimal reagent con-
centrations. For all functional studies, cells were kept over-
night in RPMI 10% FCS at 37C and 5% CO2. Before
staining, CD8pos T-cells were enriched using a MiniMACS
device (Miltenyi Biotec, Bergisch Gladbach, Germany) result-
ing in >90% CD3pos CD8pos cells. Cells (106) were incubated
with tetramers (1 lg ml1, 60 min, 4C) and then with anti-
bodies (30 min, 4C). For intracellular assessment of cyto-
kines, 106 MiniMACS puriﬁed CD8pos T-cells were ﬁrst pre-
stained with PE-labeled tetramers for 30 min at 4C.
Without this prestaining, the visualization of antigen-speciﬁc
T-cells would be inefﬁcient due to TCR downregulation
(Supporting Information Fig. 1), precluding comprehensive
quantiﬁcation of functional cells among antigen-speciﬁc
T-cell populations. Then, they (4  105 T-cells) were incu-
bated with 2  105 T2 cells at 37C for 4 hr with or without
10 lM peptide (Melan-A/MART-1 ELAGIGILTV, or EBV
GLCTLVAML) and anti-CD107aFITC (BD PharMingen),
whereby 10 lg ml1 Brefeldin A (Sigma, St. Louis, MO) was
added for the last 3 hr, in culture medium consisting of
IMDM supplemented with 0.55 mM Arg, 0.24 mM Asn, 1.5
mM Gln, and 8% pooled human Apos serum (‘‘complete me-
dium’’). T2 cells were used because of their enhanced stimu-
latory capacity related to membrane expression of costimula-
tory molecules, and TAP deﬁciency resulting in high density
of speciﬁc pMHC complexes after peptide loading. Subse-
quently, cells were stained at 4C with PE-labeled tetramers,
anti-CD8, anti-CD28 and anti-CD45RA antibodies. For dead
cell exclusion, cells were stained with live/dead ﬁxable dead
cell violet stain (Molecular Probes/Invitrogen). Then, cells
were permeabilized with 0.1% saponin at 4C, washed, and
stained for 40 min with anti-IFNcPE-Cy7, anti-TNFaAlexa700
and anti-IL-2allophycocyanin (all BD PharMingen). CD8pos
T-cells/sample (5  105) was acquired with a ﬂow cytometry
LSR IITM machine. The cytometer performance was checked
daily using the CST (BDTM Cytometer Setup and Tracking)
quality control beads system according to the manufacturer’s
instructions. All ﬂow cytometer data of this study were ana-
lyzed with FlowJoTM software (TreeStar). Results of tetramer-
pos T-cells were calculated and are indicated in percentages of
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Figure 1. T-cell frequency, cytokine production and degranulation. Melanoma patients received monthly peptide vaccinations. PBMCs were
prepared from blood withdrawn 1 week after booster vaccination, and analyzed by ﬂow cytometry ex vivo. (a) Frequencies of tumor-speciﬁc
T-cells before vaccination, after vaccination without CpG (11 patients), and with CpG (24 patients). (b) Direct ex vivo analysis of tetramer
gated T-cells for cytokine production (IFNc, TNFa, IL-2) and degranulation (CD107a/LAMP-1), after 4 hr incubation with peptide pulsed T2
cells. (c) Representative example dot plots. Left side: Melan-A-speciﬁc T-cells from patient LAU 1264 (2.88% A2/Melan-A tetramerpos cells,
withdrawn 1 week after four vaccinations); right side: EBV-speciﬁc T-cells from healthy donor (HD) BCL3 (0.23% A2/EBV tetramerpos cells).
(d) Comparison of tumor-speciﬁc T-cells (after vaccination with CpG) with EBV-speciﬁc T-cells from untreated HDs and patients. EBV
(BMLF1) speciﬁc T-cells were analyzed from healthy donors (HD) and from the 24 patients after vaccination ‘‘with CpG’’ [the latter results
are identical to (b)]. (e) Cytokine coexpression and degranulation was analyzed with SPICE software.21 Data are from CD8pos T-cells
withdrawn after a mean of 6 6 4 monthly vaccinations, at the time of (nearly) maximal frequency of A2/Melan-A tetramerpos cells reached
per patient (Supporting Information Table 1A). *p < 0.05; **p < 0.01; *** p < 0.001; no symbol, not signiﬁcant.
circulating CD8pos T-cells. Geometrical mean ﬂuorescence in-
tensity (GMFI) was used to quantify TCR and CD8 expres-
sion levels. To compensate for day-to-day variations, the val-
ues were normalized based on the GMFI of tetramer-negative
CD8 T-cells.
Detection of pSTAT1 and pSTAT5
PBMCs were stained ﬁrst with tetramers for 30 min, washed
and stained with anti-CD4 and anti-CD8 mAbs for 20 min.
Cells were resuspended in RPMI 10% FCS and left for 1 hr
at 37C and 5% CO2. Then cells were stimulated for 15 min
with either IL-2 (100 ng ml1) and IL-15 (10 ng ml1) or
IFNa (1,000 U ml1) and IFNc (1,000 U ml1). Samples
were ﬁxed by addition of equal volumes of ﬁxing solution
(1% formaldehyde, 2% glucose and 5 mM NaN3) for 15 min
at 37C and 5% CO2, washed and permeabilized with Perm
Buffer III (BD Biosciences) for 30 min at 4C. The samples
were washed two times, resuspended in 15 ll staining buffer
and 5 ll of each BD Phosﬂow anti-STAT1(pY701)-Alexa 647
and anti-STAT5(pY694)-A488 (BD Biosciences) were added
for 30 min at 4C. Finally, cells were washed and analyzed
on a Gallios Flow cytometer (Beckman Coulter).
CD3 zeta chain analysis
CD8 T-cells were enriched using the CD8 MiniMACS system
from Miltenyi. Isolated CD8 T-cells were stained ﬁrst with
tetramers for 30 min, washed and stained with anti-CD8
antibody for 20 min. To exclude dead cells, samples were
incubated with live/dead ﬁxable aqua stain (Invitrogen), fol-
lowed by intracellular staining of CD3 zeta chain antibody/
CD247 (AbD serotech) in presence of 0.1% saponin. As con-
trol we used the corresponding IgG2a isotype antibody. Sam-
ples were washed and analyzed on the Gallios Flow
cytometer.
Tetraphosphoﬂow assay
We developed a novel technique for ex vivo detection of
pERK1/2 in antigen-speciﬁc T-cells. CD8 T-cells were
enriched using the CD8 MiniMACS system from Miltenyi,
followed by staining ﬁrst with tetramers for 30 min, washing
and staining with anti-CD8 antibody for 20 min. Cells were
cultured in RPMI 10% FCS for 1 h at 37C and 5% CO2. In
the meantime, T2 stimulator cells were pulsed with 10 lM
peptides for 1 hr, washed and resuspended in RPMI 10%
FCS. CD8 T-cells were coincubated with T2 stimulator cells
(after 1 min centrifugation) for 10 min, in absence or pres-
ence of IL-2 (100 ng ml1). As controls, CD8 T-cells were
incubated with unpulsed T2 cells, or with 80 nM PMA. Sam-
ples were ﬁxed immediately with BD Cytoﬁx ﬁxation buffer
for 15 min at 37C and 5% CO2, washed and permeabilized
with Perm Buffer III (BD Biosciences) for 30 min at 4C.
Samples were washed two times, resuspended in 20 ll stain-
ing buffer and 5 ll of BD Phosﬂow anti-ERK1/2 (pY202/
pY204) antibody were added for 30 min at room tempara-
ture. Samples were washed and analyzed on a Gallios Flow
cytometer.
Data analysis and statistics
Analysis of coproduction of cytokines and degranulation in
Figure 1e was performed with SPICE software version 5.1.21
With the aim of ranking patients with respect the multifunc-
tional T-cells, we calculated a ‘‘functional T-cell score’’ based
on the four functions analyzed (IFNc, TNFa, IL-2 and
CD107a). The formula was: score ¼ 1% cells with one
function þ 2% cells with two functions þ 4% cells with
three functions þ 8% cells with four functions. Statistical
signiﬁcance was assessed by the nonparametric Mann–Whit-
ney test or the parametric student t test, where appropriate. p
values less than 0.05 were considered signiﬁcant. Box-and-
whisker plot representations were designed with boxes indi-
cating 25–75 percentiles, whiskers 10–90 percentiles, and hor-
izontal bars and ‘‘þ’’ within the box median and mean val-
ues, respectively.
Results
Functionally competent tumor-speciﬁc T-cells induced by
vaccination with peptide and CpG
Melanoma patients received monthly s.c. injections of Melan-
A/MART-1 peptide26-35 and CpG, emulsiﬁed in IFA. This
vaccine induced high frequencies of circulating Melan-A/
MART-1 speciﬁc T-cells17 (hereafter called ‘‘tumor-speciﬁc
T-cells’’). T-cell frequencies were very much higher than
before vaccination, and also much higher (about 10) than
in patients vaccinated with the same peptide without CpG
(Fig. 1a and Ref. 17). To investigate the functional compe-
tence of T-cells, we performed multiparameter ﬂow cytome-
try assays after 4 hr triggering with peptide, allowing simulta-
neous assessment of cytokine production and degranulation.
Many tumor-speciﬁc T-cells were functionally competent, as
they produced IFNc, TNFa and IL-2, and upregulated
CD107a (LAMP-1), a marker for degranulation and cytotox-
icity8,9 (Figs. 1b and 1c and Supporting Information Table
1A). T-cell function was highly signiﬁcantly increased as
compared to T-cells from before vaccination, and after vacci-
nation without CpG (Fig. 1b). As a reference, we analyzed T-
cells speciﬁc for the HLA-A2-restricted epitope
GLCTLVAML derived from the EBV lytic protein BMLF1,
and found relatively similar functional competence (Figs. 1c
and 1d and Supporting Information Table 1B). IFNc and IL-
2 productions were similar, but degranulation and TNFa
production were less frequent in tumor- than in virus-speciﬁc
T-cells (Fig. 1d). Interestingly, the function of EBV-speciﬁc
T-cells was similar in patients and untreated healthy donors
(Fig. 1d), which was also revealed by the evaluation of cells
with 0, 1, 2, 3 or all of the 4 functions analyzed (Fig. 1e).
Typical for CD8 T-cells, IL-2 was less frequently produced,
which was the case in both tumor- and virus-speciﬁc T-cells.
With the aim to obtain a single numeric value characteriz-
ing the functional competence of each T-cell population, we
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calculated a ‘‘functional T-cell score’’ (described in Methods).
Using this score, the data again showed enhanced T-cell
function when CpG was added to the vaccine formulation
(Fig. 2a), conﬁrming the results obtained for the four
individual T-cell functions (Fig. 1b). The scores also con-
ﬁrmed that EBV-speciﬁc T-cells were of similar functional
competence in healthy controls and patients, whereas the tu-
mor-speciﬁc T-cells were slightly inferior (Fig. 2b). The indi-
vidual patient data showed large interindividual differences,
from strong to modest, and in one patient (LAU 936) even
‘‘nonfunctional’’ tumor-speciﬁc T-cells (Supporting Informa-
tion Table 1). We analyzed patients without vs. with metasta-
ses at the time of T-cell analysis, and found that only the lat-
ter had lower scores of tumor-speciﬁc T-cells when
compared to virus-speciﬁc T-cells (Fig. 2c). Therefore, the
overall slightly inferior functionality of tumor- as compared
to EBV-speciﬁc T-cells (Fig. 1d) was likely due to the reduced
function of tumor-speciﬁc T-cells from tumor bearing
patients (Fig. 2c). However, after CpG-based vaccination even
these patients generated T-cells with highly signiﬁcantly
enhanced function as compared to before vaccination, and to
patients after vaccination without CpG (Fig. 2d). Finally, we
analyzed the patient’s clinical outcome, and found that dis-
ease-free survival was signiﬁcantly increased in patients who
had T-cells above the half maximal score (Fig. 2e). The
results for overall survival of patients pointed in the same
direction, but the difference to patients with T-cells below
the half maximal score did not reach statistical signiﬁcance
(Fig. 2f).
Frequencies and percentages of CD28neg Melan-A/MART-1
speciﬁc T-cells correlate with function
Strong CD8 T-cell responses are known to be associated with
enhanced effector cell differentiation and function.15 Not sur-
prisingly, we found that patients exhibiting high percentages
(>0.5%) of tumor-speciﬁc T-cells had signiﬁcantly enhanced
functions on a per T-cell basis, for CD107a, IFNc and TNFa.
By contrast, IL-2 production was similar to patients reaching
only lower (<0.5%) percentages of tumor-speciﬁc T-cells
(Fig. 3a). Effector cell differentiation can be assessed by
changes of cell surface receptors. We have previously shown
that most antigen-speciﬁc T-cells became CCR7neg CD45RA-
neg effector memory cells after vaccination with peptide and
CpG.17 More extended phenotyping revealed that variable
proportions of vaccine responding T-cells were CD28neg (Fig.
3b) which is characteristic for advanced differentiation of vi-
rus-speciﬁc CD8 T-cells.22 This is not usually observed after
T-cell vaccination, except after vaccination with peptide and
CpG. When comparing patients with strong T-cell responses
(>0.5% of tumor-speciﬁc cells) with those with weaker T-cell
responses, we found that the former contained signiﬁcantly
higher proportions of CD28neg cells (Fig. 3b), which were
more often positive for CD107a and IFNc, and a similar
trend for TNFa (Fig. 3c), conﬁrming strong effector function
for CD28neg cells. Finally, we analyzed TCR and CD8 expres-
sion levels. As compared to CD28pos cells, CD28neg cells
showed similar TCR but lower CD8 expression, possibly
related to their enhanced function associated with more
pronounced ‘‘tuning’’ via CD8 downregulation in vivo.23
Figure 2. Comparisons based on a functional T-cell score, and
correlation with patient survival. For each T-cell population, we
determined a score, i.e., a quantitative value for the combined
IFNc, TNFa, IL-2 and CD107a expression (described in Methods)
(a,b) T-cell scores from patients and healthy donors, generated
from the same data as shown in Figs. 1b and 1d, respectively,
conﬁrming the identiﬁed differences between cohorts.
(c) Comparison of T-cells speciﬁc for EBV vs. Melan-A from
disease-free patients (n ¼ 13) and patients with metastases
(n ¼ 11). (d) Comparison of scores from Melan-A speciﬁc T-cells
from patients ‘‘before vaccination,’’ after vaccination ‘‘without
CpG,’’ and after vaccination ‘‘with CpG,’’ depending on absence or
presence of metastases at the time of T-cell analysis (from the
same data as shown in Figs. 1b and 2c). (e,f) Kaplan–Meier curves
for disease-free survival (e) and overall survival (f) from patients
with T-cells scoring equal or above vs. below 50% of the highest
score reached (10 vs. 14 patients, respectively). The 50% max
score was 181 (Supporting Information Table 1). *p < 0.05;
**p < 0.01; ***p < 0.001; no symbol, not signiﬁcant.
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After 4-hr triggering with peptide, we found signiﬁcant
downregulation, which was evident for both TCR and CD8,
and similar for CD28pos and CD28neg T-cells (Fig. 3d).
T-cell responses independent of patient age and gender
Previous studies have suggested that T-cell responses decline
with age.24 Because our study population varied largely with
respect to patient age, it was possible to analyze its impact.
However, we found no signiﬁcant correlations with frequency
of tumor-speciﬁc T-cells after vaccination with CpG, IFA and
peptide. Similarly, we found no signiﬁcant differences of T-
cell function between younger and older individuals (Fig. 4).
Finally, patient gender did not correlate with frequency and
function of tumor-speciﬁc T-cells (not shown).
Efﬁcient phosphorylation of STAT1 and STAT5
Previous studies have shown that T-cells of cancer patients
may have functional defects in cytokine signaling.25,26
Because STATs play a central role,27 we analyzed STAT
phosphorylation after 15-min stimulation with the common-
c chain cytokines IL-2 and IL-15. Interestingly, tumor-
speciﬁc T-cells after vaccination with CpG showed similar
frequencies of STAT5(pY694) positive cells as EBV-speciﬁc
cells (Figs. 5a and 5c). Total CD8 T-cells from patients were
slightly lower, and CD4 T-cells higher. As expected, this
Figure 3. Enhanced function of strongly expanded T-cells, concomitant with increased percentages of CD28neg T-cells. (a) Comparison of
function [degranulation (CD107a) and production of cytokines] by T-cells from patients with low (<0.5%) vs. high (>0.5%) percentages of
A2/Melan-A tetramerpos T-cells in PBMC. (b) Example dot plot from CD8pos gated T-cells from patient LAU 1106, with 2.73% A2/Melan-A
tetramerpos T-cells, including the two subpopulations of CD28neg (79%) and CD28pos (21%) cells. Signiﬁcantly increased (p < 0.01)
frequency of CD28neg cells among A2/Melan-A tetramerpos T-cells in patients with high frequencies (>0.5%) of A2/Melan-A tetramerpos
T-cells. (c) Comparison of function by CD28pos vs. CD28neg T-cells. (d) Mean ﬂuorescence intensity of TCR (tetramer) and CD8, expressed by
CD28pos and CD28neg Melan-A/MART-1 speciﬁc T-cells. Although desirable, such analysis (e.g., of subpopulations of antigen-speciﬁc
T-cells) from before immunotherapy and after vaccination without CpG was not possible because of low T-cell frequencies.
Figure 4. T-cell frequency and function in relation to patient age.
T-cell frequency and function are shown at the time point of maximally
reached % A2/Melan-A tetramerpos T-cells per patient, i.e., after a mean
of 8 (65) monthly vaccinations. Patient age did also not correlate with
the other three functional parameters, i.e., CD107a, TNFa and IL-2 of
Melan-A speciﬁc T-cells (not shown). [Color ﬁgure can be viewed in the
online issue, which is available at wileyonlinelibrary.com.]
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stimulation with IL-2/IL-15 induced stronger phosphorylation
of STAT5 (pY694) than STAT1 (pY701). In contrast, stimula-
tion with IFNa and IFNc triggered stronger phosphorylation of
STAT1 than STAT5 (Figs. 5b and c). There was no difference
between EBV- and tumor-speciﬁc T-cells. Together, these data
demonstrate intact STAT1/5 signaling by tumor antigen-spe-
ciﬁc T-cells after vaccination with peptide and CpG. Note that
with the exception of data labeled with ‘‘before vaccination’’ or
with ‘‘without CpG’’ (Figs. 1a and 1b, 2a and 2d), all data for
tumor-speciﬁc T-cells in this article are from the 24 evaluable
patients vaccinated with CpG. Although we attempted to also
characterize T-cells from patients before vaccination or after
vaccination without CpG, there were not enough tumor-speciﬁc
T-cells available for performing all the functional assays used in
this study. These restrictions apply also to most other studies of
T-cell based therapy in humans.28
Expression of CD3 zeta chain and phosphorylation of
ERK1/2
T-cells from cancer patients have been suggested to express
abnormally low levels of the CD3 zeta chain,29 which was
however not conﬁrmed in another study.30 We found similar
intracellular CD3 zeta chain expression by total CD8 T-cells
and tumor- and virus-speciﬁc T-cells (Figs. 6a and 6b). In
turn, the importance of the MAP kinase for T-cell responses is
well known.31 Therefore, we developed a novel ‘‘tetraphospho-
ﬂow assay’’ combining the known phosphoﬂow technology32
with tetramers, allowing the identiﬁcation of ERK1/2 (pY202/
pY204) positive cells. Ten minutes after stimulation with pep-
tide, distinct populations of pERK1/2pos T-cells were detected
with remarkably bright staining (Figs. 6c and 6d). Earlier and
later time points showed lower percentages and intensities for
pERK1/2 staining (data not shown). Both tumor-speciﬁc and
EBV-speciﬁc T-cells were signiﬁcantly more frequently
pERK1/2pos after stimulation with cognate peptide antigen as
compared to unstimulated CD8 T-cells. Comparable results
were obtained upon addition of IL-2; there was a trend for
increased phosphorylation in EBV-speciﬁc T-cells which was
however not signiﬁcant. Control stimulation with PMA
showed signiﬁcantly higher percentages of pERK1/2pos cells,
likely due to its powerful triggering of multiple signaling path-
ways. Together, our data suggest efﬁcient TCR signaling, con-
sistent with the overall data showing functional competence of
tumor-speciﬁc T-cells after peptide/CpG vaccination.
Discussion
Multifunctional cancer-speciﬁc human T-cells have been
described previously, but after ten or more days of in vitro
Figure 5. STAT phosphorylation. Percent positive cells after 15 min stimulation with (a,c) IL-2 plus IL-15, or (b,c) IFNa plus IFNc, as
described in Methods. Data on tumor-speciﬁc, and total CD8þ and CD4þ T-cells are from 19 patients, and on EBV-speciﬁc CD8þ T-cells
from four healthy donors and three patients, i.e., whenever enough cells were available for analysis. (c) Representative histograms from
patient LAU 972 and HD BCL3 (for EBV), with indication of percent positive cells. No signiﬁcant differences were found in EBV-speciﬁc
T-cells from untreated HD vs. patients (not shown).
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stimulation.33 In contrast, multifunctional virus-speciﬁc T-
cells have been shown by direct ex vivo analyses.34 With the
latter approach, we show here multiple functions of human
tumor-speciﬁc CD8 T-cells in most patients of our study. In
disease-free patients, T-cell functions were comparable to vi-
rus-speciﬁc CD8 T-cells, suggesting protective potential. The
present data are in agreement with our previous report17 that
vaccination with peptide, CpG and IFA induced higher CD8
T-cell numbers and more pronounced effector differentiation
than vaccination with DNA, recombinant viral vectors, or
peptides and proteins in vaccine formulations without CpG.22
Following multiple booster vaccinations, T-cell responses
were maintained at high levels over extended periods of time,
conﬁrming previous data on cancer-speciﬁc human CD8 T-
cells.35,36
The functionality on a per T-cell basis was increased in
patients with high T-cell frequencies, as observed previously
in mice and humans.35,37 Moreover, high frequency T-cell
populations exhibited high proportions of CD28neg cells,
which showed enhanced effector function as compared to
CD28pos cells (the latter including memory cells), indicating
that CD28neg populations are enriched for effector cells.
Strong and continued T-cell activity was associated with per-
sistence of codominant clonotypes, which were not limited
by replicative senescence or functional alterations (36 and
manuscript in preparation). Thus, strong T-cell responses
dominated by advanced differentiated CD28neg T-cells may
be highly functional and can persist over many years.35,36
It has been suggested that increased incidence of infection
and cancer of elderly individuals may be related to functional
T-cell deﬁciencies.24 A recent mouse study indicated that the
appropriate choice of state-of-the-art vaccine adjuvants may
overcome such deﬁcits.38 Indeed, our ﬁndings of vigorous
self/tumor-speciﬁc T-cell responses even in elderly patients
conﬁrm that adjuvants such as CpG successfully promote
strong T-cell responses independent of age.
We analyzed STAT phosphorylation, since recent studies
had demonstrated defective signaling upon stimulation with
interferon25 and with IL-226 in circulating total CD8 and
CD4 T-cells from melanoma patients. In contrast, our data
revealed similar STAT phosphorylation in tumor- and virus-
speciﬁc T-cells. Furthermore, functional T-cell competence
depends on intact TCR signaling, whereby the MAP kinase
pathway plays a major role.31 Our novel method allowing
Figure 6. Expression of CD3 zeta and phosphorylation of ERK1/2. (a,b) Staining for CD3 zeta chain was done ex vivo, after cell membrane
permeabilization, and analyzed by gating on total CD8þ T-cells and T-cells positive for A2/Melan-A and A2/EBV tetramers.
(a) Representative histograms from patient LAU 1106 and HD BCL3 (for EBV). (b) Percent CD3 zeta positive cells from 16 patients and 5
healthy donors. Isotype control values were statistically signiﬁcantly lower (p < 0.001) than CD8þ, Melan-A and EBV-speciﬁc T-cells; no
signiﬁcant differences between the latter three. (c,d) To determine ERK phosphorylation, T-cells were analyzed ex vivo, by a novel
‘‘tetraphosphoﬂow assay.’’ (c) Percentages of phosphoERK1/2þ T-cells after 10-min incubation with unlabelled T2 cells (‘‘-’’), or T2 cells
pulsed with cognate peptide, in absence or presence of IL-2 (100 ng ml1). Data are from 14 patients and 11 healthy donors. The values
from Columns 2, 3, 4, and 5 are statistically signiﬁcantly higher than Column 1 (p < 0.001), and lower than Column 6 (p < 0.05).
(d) Representative histograms from patient LAU 1106 for Melan-A (left) and HD BCL7 for EBV-speciﬁc T-cells (right), with indication of
percentages of pERK1/2 positive cells. No signiﬁcant differences were found in EBV-speciﬁc T-cells from HD vs. patients (not shown). All
the data in this article are from experiments performed directly ex vivo, i.e., with T-cells without keeping them in culture for (many) days.
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identiﬁcation of pERK1/2 positive cells among antigen-spe-
ciﬁc T-cells revealed similar results in tumor- and virus-spe-
ciﬁc T-cells. Thus, after CpG based vaccination, these signal-
ing events appear intact. However, direct comparison with
antigen-speciﬁc T-cells from nonvaccinated cancer patients is
still lacking, due to the limited availability of un-manipulated
cells, i.e., cells that have not been cultured for days or weeks.
Further technical improvements are necessary for compre-
hensive characterization of signaling pathways in small num-
bers of tumor-speciﬁc T-cells. In general, many more studies
are required for understanding T-cell signaling, including its
differences between humans and mice.31
With regard to clinical results, we found that T-cell func-
tion correlated signiﬁcantly with disease-free survival of
patients. A trend was also found for overall survival, but
without reaching statistical signiﬁcance. However, our study
was a Phase I clinical trial and not randomized, indicating
that these ﬁndings represent preliminary evidence. Neverthe-
less, our data are compatible with the notion that functionally
competent tumor-speciﬁc CD8 T-cells may be clinical
meaningful.
Patients with massive tumor burden are less likely to
respond to immunotherapy,39 a notion that becomes increas-
ingly acknowledged together with identiﬁcation of various
mechanisms used by tumors to suppress anti-tumor immune
responses.40–42 Therefore, immunotherapy may preferentially
be successful in patients with minimal residual disease, after
early diagnosis and/or after complete surgical tumor resec-
tion. Although the majority of our patients had functionally
competent T-cells, CD8 T-cells showed tendencies of lower
cytokine production and degranulation in patients bearing
metastases as compared to disease-free patients. Future stud-
ies will focus on patient heterogeneity and identify mecha-
nisms responsible for the impaired T-cell responses.40–42 In
this regard, more detailed characterization of immune cell
function is necessary not only for circulating cells, but also
for cells directly isolated from tumor tissue. These aims were
beyond the scope of the present manuscript and require col-
lection of large amounts of tumor tissue.
We have previously reported signiﬁcantly different T-cell
responses in patients after vaccination with the analog ELA-
GIGILTV decapeptide as opposed to the natural EAAGI-
GILTV decapeptide. The analog peptide induced frequencies
of Melan-A/MART-1 speciﬁc T-cells that were about twice as
high than vaccination with the natural peptide. In contrast,
the natural peptide triggered T-cells with higher functional
avidity TCRs and enhanced IFNc production.43 However, a
minority of patients responded only very weakly to the natu-
ral peptide. In this study, 10/24 patients were vaccinated with
the natural, and 14/24 patients with the analog peptide (Sup-
porting Information Table 1A). It was important to deter-
mine whether T-cell function depended on vaccination with
natural vs. analog peptide. However, this was not the case,
since degranulation and cytokine production were similar in
the two patient groups (Supporting Information Table 1A).
This was not surprising, since functional testing by triggering
the T-cells with the analog Melan-A peptide does not reveal
signiﬁcant differences, whereas testing with natural peptide
demonstrates superior functionality after vaccination with
natural as opposed to analog vaccination.43 In this study we
used the analog peptide for functional testing because of the
increased peptide/MHC stability important for assay reprodu-
cibility. Unfortunately, analyzing all patients and samples in
all functional assays with both analog and natural peptide
was not possible due to the limited availability of cells.
Therefore, we currently develop novel molecular and func-
tional assays allowing the reliable assessment of T-cell func-
tion with small cell numbers. These assays will be applied for
all patients with available cells. Thus, it remains to be deter-
mined whether vaccination with the natural peptide results in
superior T-cell function beyond the known enhanced IFNc
production.43
The natural and analog peptides represent very highly
cross-reactive epitopes compatible with the similar conﬁgura-
tion of the two peptide/MHC complexes.44 We generated
>1,000 T-cell clones, and did not ﬁnd a single clone binding
tetramers constructed with one but not the other peptide/
MHC complex.43,45 Similarly, cross-reactivity was always
observed in functional assays, despite the quantitative differ-
ences found in peptide titration studies, with enhanced recog-
nition of target cells labeled with natural peptide by T-cells
from patients after vaccination with natural peptide.43 Never-
theless, this system reveals a very high degree of cross-reac-
tivity to self/tumor antigen. The characterization of ﬁne dif-
ferences of T-cell receptors and T-cell function after
vaccination with natural vs. analog peptide remains challeng-
ing,45 but is important in order to determine whether analog
peptide vaccination remains an option in patients not
responding to the natural peptide, or for enhanced boosting
after priming with natural peptide.
Our ﬁndings of functionally competent self/tumor-speciﬁc
T-cells are in disagreement with results showing that mecha-
nisms of self-tolerance may impair T-cell function.46,47 T-cells
with high afﬁnity TCRs to self are eliminated in the thymus,
which is likely also happening to some Melan-A/MART-1
speciﬁc T-cells,35 resulting in deﬁciency of high afﬁnity
TCRs. We continue to study the TCR repertoires of human
cancer-speciﬁc T-cells; including the concern that immuno-
therapy may activate low afﬁnity T-cells that are unable to
recognize naturally presented antigen. However, the majority
of T-cells analyzed in this study have competent TCRs capa-
ble to recognize tumor cells.43 Furthermore, recent studies
suggest that low/intermediate avidity T-cells may have pro-
tective potential.48 Many studies have shown that T-cells may
be tolerized in the periphery,49 e.g., by mechanisms of anergy
and/or deletion of self-speciﬁc T-cells. Very recently, we
demonstrated that circulating Melan-A/MART-1 speciﬁc T-
cells had a gene expression proﬁle of functional effector cells
after vaccination with CpG, which was largely different in
melanoma metastases where they showed signiﬁcant
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molecular hallmarks of exhausted cells.50 In contrast, after
vaccination without CpG or in absence of immunotherapy,
T-cells were poorly functional. Thus, self/tumor-speciﬁc T-
cells may be functionally deﬁcient due to insufﬁcient T-cell
stimulation, which is unfortunately the case for the majority
of human T-cell vaccines, hence the need for improvement
to achieve therapeutic efﬁcacy.15 Our data provide the
rational basis for Phase III clinical trials with efﬁcient T-cell
vaccines, with the aim to determine whether this type of
immunotherapy is indeed capable of improving clinical
outcomes.
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